SHIP OF THESEUS

Technology: Ship of Theseus is developing a proprietary suite of enhanced HOX protein biologics (HOX+). This technology leverages modifications made to the degron region of HOX molecules to extend intracellular halflife. HOX genes are master regulators of many context-specific cell phenotypes... HOX proteins are difficult to target with cell or nuclear specificity and possess an intracellular half-life on the order of minutes, requiring heavy, repeat dosing. HOX+ modified proteins enter cells within minutes of exposure and resist intracellular degradation for several days, reducing dose frequency and mass. In the clinical setting, HOX+ can be shipped and applied in situ rather than requiring ex vivo culture in a specialized facility.